Inflammatory Treatment Articles & Analysis
25 news found
To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, toothaches, menstrual pain and headaches. ...
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. ...
“We are all united by our ultimate mission of bringing world-class care and treatment to patients around the world, and we strive to foster a culture that encourages collaboration and visionary thinking to help us drive our innovation ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important ...
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are qualified for ...
Patients whose lungs have untreated collateral ventilation (CV+) are currently ineligible for treatment with Zephyr Valves and have limited options once medical management alone does not control symptoms. ...
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening ...
About Siolta Therapeutics Siolta Therapeutics is a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics for the prevention and treatment of inflammatory, chronic, and life-threatening diseases. STMC-103H, currently in Phase 1b/2 development in the US (NCT05003804), is designed to trigger tolerant immunological ...
1 Establishment of new drug pipeline with bilirubin platform technology Securing global competitiveness by increasing corporate value “I want to give hope to those who are living a difficult life with an incurable disease” [IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, ...
Myung-Rip Kim, CEO of Vilix said, “The research team led by Professor Sang-Yong Jeon of KAIST’s research team has proven the effectiveness of treatment in eight animal models of eight types of disease as a way to solve the hydrophobicity of bilirubin over the past 7 years, and based on this, the publication was ...
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water. It is Bilix that solved this problem. ...
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. ...
Invizius will use the financing to complete a First-in-Man safety study in 2022 of its H-Guard® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis. There are currently 3.3 million haemodialysis patients worldwide who receive treatment multiple times a week. ...
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to ...
“We will make ‘bilirubin,’ a substance with antioxidant effects that removes harmful free radicals, as a disease treatment for the first time in the world.” “Over 20,000 papers since 1987 have shown that bilirubin has a therapeutic effect on various diseases,” said Myung-Lip Kim, CEO of Bilix, a bio company developing new drugs that we met ...
Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in targeted populations. The lead program, focused on alleviating allergic diseases, aims to stop asthma before it starts through the disruption of the atopic march. ...
(NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally. ...
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. ...